1,3-benzothiazol-2-yl(2-{[2-(3,4-dimethoxyphenyl)ethyl]amino}pyrimidin-4-yl)acetonitrile | 848344-01-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,3-benzothiazol-2-yl(2-{[2-(3,4-dimethoxyphenyl)ethyl]amino}pyrimidin-4-yl)acetonitrile
• 英文别名: 2-(1,3-Benzothiazol-2-yl)-2-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]acetonitrile
• CAS: 848344-01-4
• 化学式: C₂₃H₂₁N₅O₂S
• 分子量: 431.518
• InChiKey: KSTCTALKPRMJBB-UHFFFAOYSA-N

物化性质

• 沸点：
  651.3±65.0 °C(Predicted)
• 密度：
  1.317±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  121
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• Benzazole derivatives and their use as jnk modulators
  申请人：——

  公开号：US20030162794A1

  公开（公告）日：2003-08-28

  The present invention is related to benzazole derivatives notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such benzazole derivatives. Said benzazole derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK2 and/or 3. The present invention is furthermore related to novel benzazole derivatives as well as to methods of their preparation. 1 X is O, S or NR 0 , with R 0 being H or an unsubstituted or substituted C 1 -C 6 alkyl; G is an unsubstituted or substituted pyrimidinyl group.

  本发明涉及苯唑衍生物，特别用作药用活性化合物，以及含有该类苯唑衍生物的药物配方。所述苯唑衍生物是JNK途径的高效调节剂，特别是JNK2和/或3的高效和选择性抑制剂。本发明还涉及新型苯唑衍生物以及它们的制备方法。其中1X为O、S或NR0，其中R0为H或未取代或取代的C1-C6烷基；G为未取代或取代的嘧啶基团。
• Benzazole derivatives for the treatment of scleroderma
  申请人：Gotteland Jean-Pierre

  公开号：US20050119277A1

  公开（公告）日：2005-06-02

  The present invention is related to the use of benzazole derivatives of formula (I) for the treatment and/or prevention of scleroderma and its therapeutic implications selected in the group consisting of systemic sclerosis, scleroderma-like disoders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, Dupuytren's contracture, keloid and other scarring/wound healing abnormalities, postoperative adhesions and reactive fibrosis, as well as chronic heart failure, in particular after myocardial infarction.

  本发明涉及使用式(I)的苯并咪唑衍生物治疗和/或预防硬皮病及其治疗意义，所述治疗意义选自以下组中的系统性硬化症、类硬皮病、单纯性硬皮病、肝硬化、间质性肺纤维化、杜普伊特伦收缩、瘢痕和其他瘢痕/伤口愈合异常、术后粘连和反应性纤维化，以及慢性心力衰竭，特别是心肌梗死后。
• METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK
  申请人：Halazy Serge

  公开号：US20070259892A1

  公开（公告）日：2007-11-08

  The present invention is related to benzazole derivatives notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such benzazole derivatives. Said benzazole derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK2 and/or 3. The present invention is furthermore related to novel benzazole derivatives as well as to methods of their preparation. X is O, S or NR 0 , with R 0 being H or an unsubstituted or substituted C 1 -C 6 alkyl; G is an unsubstituted or substituted pyrimidinyl group.

  本发明涉及苯并咪唑衍生物，特别是用作药物活性化合物，以及包含这种苯并咪唑衍生物的制药配方。这些苯并咪唑衍生物是JNK途径的有效调节剂，特别是JNK2和/或3的有效和选择性抑制剂。本发明还涉及新型苯并咪唑衍生物及其制备方法。其中，X为O、S或NR0，其中R0为H或未取代或取代的C1-C6烷基；G为未取代或取代的嘧啶基团。
• BENZAZOLE DERIVATIVES AND THEIR USE AS JNK MODULATORS
  申请人：Applied Research Systems ARS Holding N.V.

  公开号：EP1240164A1

  公开（公告）日：2002-09-18
• BENZAZOLE DERIVATIVES FOR THE TREATMENT OF SCLERODERMA
  申请人：Applied Research Systems ARS Holding N.V.

  公开号：EP1450792B1

  公开（公告）日：2006-09-27